Genentech
Genentech, a member of the Roche Group, is a pioneering biotechnology company headquartered in South San Francisco, US. Founded in 1976, Genentech has been at the forefront of the biotechnology industry, focusing on the development of innovative medicines for serious medical conditions. The company is renowned for its contributions to oncology, immunology, and neuroscience, with a portfolio that includes groundbreaking therapies such as Herceptin and Avastin. With a commitment to research and development, Genentech has achieved numerous milestones, including the first-ever recombinant DNA product approved by the FDA. Its unique approach to drug development, combining cutting-edge science with a patient-centric philosophy, has solidified its position as a leader in the biopharmaceutical market. Genentech continues to set benchmarks in the industry, driving advancements that improve patient outcomes globally.
DitchCarbon Score
How does Genentech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genentech's score of 30 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genentech's reported carbon emissions
In 2022, Genentech reported total carbon emissions of approximately 4,550,518,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 4,550,518,000 kg CO2e. Specifically, Scope 1 emissions were approximately 249,961,000 kg CO2e, and Scope 2 emissions totalled around 114,519,000 kg CO2e. The company has not disclosed specific reduction targets or initiatives as part of its climate commitments. However, it is essential to note that Genentech operates within the biopharmaceutical industry, which is increasingly focusing on sustainability and reducing carbon footprints. The absence of defined reduction targets suggests that while Genentech is aware of its emissions, it may still be in the process of developing a comprehensive strategy to address climate change effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2004 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 2,022,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 54,533,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 3 | 21,308,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genentech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
